Durkee-Shock et al. (2026)
- Authors: Jessica Durkee-Shock, Meghna Bagchi, Masaru Kanekiyo, Philip J. M. Brouwer, Gunilla B. Karlsson Hedestam
- Institutes: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
- Publisher: Oxford University Press
- Link: DOI
Summary
This trial represents a major milestone in EBV research, providing the first human evidence that nanoparticle technology can generate potent, durable immunity against the virus. For the ME/CFS community, this progress is vital as EBV-induced mononucleosis is a primary risk factor for developing chronic fatigue syndromes. Preventing the initial infection could theoretically prevent a significant percentage of new ME/CFS cases.
What was researched?
This Phase I clinical trial evaluated the safety and immune response of a novel EBV gp350 ferritin nanoparticle vaccine 💊 adjuvanted with Matrix-M. The study aimed to determine if the vaccine could safely elicit protective levels of neutralizing antibodies in humans.
Why was it researched?
No approved EBV vaccine currently exists despite the virus’s association with mononucleosis, multiple sclerosis, and various cancers. Since mononucleosis is a frequent precursor to ME/CFS, a preventative vaccine could significantly reduce the population-wide risk of developing post-viral fatigue.
How was it researched?
The open-label trial enrolled 40 healthy adults split into EBV-seropositive and EBV-seronegative groups. Participants received three 50-μg doses of the nanoparticle vaccine over a six-month period. Researchers monitored safety through adverse events and measured immunogenicity using neutralizing antibody titers for up to 540 days.
What has been found?
The vaccine was well-tolerated, with most side effects being mild symptoms like injection site pain and headaches. Seronegative participants showed a 67-fold increase in neutralizing antibodies, reaching levels 3.2 times higher than natural infection titers. These elevated antibody levels remained durable for at least one year, and no seronegative participants contracted EBV during the study.
Discussion
The study was limited by its small sample size and lack of a placebo control group. However, the use of nanoparticle technology successfully mimicked the virus’s surface, leading to a much stronger immune response than previous vaccine attempts.
Conclusion & Future Work
The EBV gp350 ferritin nanoparticle vaccine is safe and highly immunogenic in humans. These results support the transition to larger Phase II trials to assess clinical efficacy in broader populations.